Alembic Pharmaceuticals Limited (APLLTD.NS)
INR 1045.0
(-1.06%)
INR 1045.0
(-1.06%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 5.75 Billion INR | 50.92% |
| 2022 | 4.37 Billion INR | -25.48% |
| 2021 | 5.87 Billion INR | -54.7% |
| 2020 | 12.96 Billion INR | 16.68% |
| 2019 | 11.11 Billion INR | 49.92% |
| 2018 | 7.41 Billion INR | 45.4% |
| 2017 | 5.09 Billion INR | -5.44% |
| 2016 | 5.39 Billion INR | -42.38% |
| 2015 | 9.35 Billion INR | 164.95% |
| 2014 | 3.53 Billion INR | 10.03% |
| 2013 | 3.2 Billion INR | 49.97% |
| 2012 | 2.14 Billion INR | 10.71% |
| 2011 | 1.93 Billion INR | 47.87% |
| 2010 | 1.3 Billion INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 1.67 Billion INR | -11.96% |
| 2023 Q2 | 1.5 Billion INR | 13.45% |
| 2023 Q1 | 1.32 Billion INR | 1.51% |
| 2023 FY | 6.6 Billion INR | 50.92% |
| 2023 Q3 | 1.99 Billion INR | 32.87% |
| 2023 Q4 | 1.9 Billion INR | -4.59% |
| 2022 Q1 | -524.4 Million INR | -2322.03% |
| 2022 Q3 | 1.69 Billion INR | 2.25% |
| 2022 Q4 | 1.3 Billion INR | -22.8% |
| 2022 FY | 4.37 Billion INR | -25.48% |
| 2022 Q2 | 1.65 Billion INR | 415.35% |
| 2021 Q1 | 1.82 Billion INR | -14.28% |
| 2021 Q2 | 2.02 Billion INR | 10.86% |
| 2021 Q3 | 1.99 Billion INR | -1.44% |
| 2021 Q4 | 23.6 Million INR | -98.82% |
| 2021 FY | 5.87 Billion INR | -54.7% |
| 2020 FY | 12.96 Billion INR | 16.68% |
| 2020 Q2 | 3.99 Billion INR | 9.24% |
| 2020 Q4 | 2.13 Billion INR | -32.97% |
| 2020 Q1 | 3.65 Billion INR | 11.15% |
| 2020 Q3 | 3.18 Billion INR | -20.4% |
| 2019 Q2 | 3.09 Billion INR | 63.35% |
| 2019 Q3 | 2.83 Billion INR | -8.51% |
| 2019 Q4 | 3.29 Billion INR | 16.21% |
| 2019 FY | 11.11 Billion INR | 49.92% |
| 2019 Q1 | 1.89 Billion INR | 28.79% |
| 2018 Q1 | 1.23 Billion INR | -12.9% |
| 2018 Q2 | 2.73 Billion INR | 121.83% |
| 2018 Q4 | 1.47 Billion INR | -30.97% |
| 2018 Q3 | 2.13 Billion INR | -22.11% |
| 2018 FY | 7.41 Billion INR | 45.4% |
| 2017 Q3 | 1.61 Billion INR | 4.96% |
| 2017 FY | 5.09 Billion INR | -5.44% |
| 2017 Q4 | 1.41 Billion INR | -12.08% |
| 2017 Q2 | 1.53 Billion INR | 92.84% |
| 2017 Q1 | 796 Million INR | -28.72% |
| 2016 FY | 5.39 Billion INR | -42.38% |
| 2016 Q1 | 1.36 Billion INR | 16.49% |
| 2016 Q2 | 1.56 Billion INR | 14.6% |
| 2016 Q3 | 1.23 Billion INR | -21.15% |
| 2016 Q4 | 1.11 Billion INR | -9.5% |
| 2015 Q4 | 1.17 Billion INR | -67.64% |
| 2015 Q3 | 3.62 Billion INR | 0.11% |
| 2015 Q2 | 3.61 Billion INR | 310.11% |
| 2015 Q1 | 882.3 Million INR | 11.37% |
| 2015 FY | 9.35 Billion INR | 164.95% |
| 2014 Q3 | 905.8 Million INR | -6.22% |
| 2014 Q2 | 965.9 Million INR | -0.08% |
| 2014 Q1 | 966.7 Million INR | 12.58% |
| 2014 FY | 3.53 Billion INR | 10.03% |
| 2014 Q4 | 792.25 Million INR | -12.54% |
| 2013 FY | 3.2 Billion INR | 49.97% |
| 2013 Q4 | 858.68 Million INR | -16.0% |
| 2013 Q1 | 714.8 Million INR | 42.63% |
| 2013 Q3 | 1.02 Billion INR | 10.27% |
| 2013 Q2 | 927.1 Million INR | 29.7% |
| 2012 Q4 | 501.14 Million INR | -21.66% |
| 2012 Q1 | 438.3 Million INR | 0.0% |
| 2012 FY | 2.14 Billion INR | 10.71% |
| 2012 Q2 | 561 Million INR | 27.99% |
| 2012 Q3 | 639.7 Million INR | 14.03% |
| 2011 FY | 1.93 Billion INR | 47.87% |
| 2010 FY | 1.3 Billion INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Sigachi Industries Limited | 1.47 Billion INR | -290.672% |
| Ind-Swift Limited | 1.22 Billion INR | -369.679% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Sakar Healthcare Limited | 495.5 Million INR | -1062.065% |
| Aurobindo Pharma Limited | 104.5 Billion INR | 94.49% |
| Innova Captab Limited | 2.53 Billion INR | -127.287% |
| Divi's Laboratories Limited | 18.31 Billion INR | 68.552% |
| AstraZeneca Pharma India Limited | 4.47 Billion INR | -28.704% |
| Morepen Laboratories Limited | 4.17 Billion INR | -37.957% |
| Mankind Pharma Limited | 40.86 Billion INR | 85.91% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Wanbury Limited | 1.7 Billion INR | -237.282% |
| Laurus Labs Limited | 3.94 Billion INR | -45.826% |
| Nectar Lifesciences Limited | 3.89 Billion INR | -48.001% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 35.873% |
| Alembic Limited | 767.77 Million INR | -649.977% |
| Hikal Limited | 1.49 Billion INR | -285.363% |
| Neuland Laboratories Limited | 5.31 Billion INR | -8.274% |
| J. B. Chemicals & Pharmaceuticals Limited | 7.54 Billion INR | 23.649% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 11.446% |
| IOL Chemicals and Pharmaceuticals Limited | 4.94 Billion INR | -16.509% |
| Themis Medicare Limited | 1.3 Billion INR | -341.875% |
| RPG Life Sciences Limited | 2.29 Billion INR | -151.193% |
| Zydus Lifesciences Limited | 45.39 Billion INR | 87.315% |
| Lupin Limited | 27.75 Billion INR | 79.256% |
| Amrutanjan Health Care Limited | 621.02 Million INR | -827.19% |
| Wockhardt Limited | 140 Million INR | -4012.929% |
| Vaishali Pharma Limited | 6.29 Million INR | -91385.542% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | -84.076% |
| Jagsonpal Pharmaceuticals Limited | 214.04 Million INR | -2590.198% |
| Jubilant Pharmova Limited | 5.18 Billion INR | -10.967% |
| FDC Limited | 3.03 Billion INR | -89.802% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 91.498% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -2667.652% |
| Eris Lifesciences Limited | 5.18 Billion INR | -11.123% |
| Venus Remedies Limited | 534.65 Million INR | -976.983% |
| ZIM Laboratories Limited | 1.09 Billion INR | -424.363% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -367.758% |
| Par Drugs and Chemicals Limited | 551.58 Million INR | -943.911% |
| Caplin Point Laboratories Limited | 7.22 Billion INR | 20.306% |
| Shilpa Medicare Limited | 3.76 Billion INR | -53.077% |
| Albert David Limited | 1.33 Billion INR | -331.494% |
| Ajanta Pharma Limited | 19.67 Billion INR | 70.737% |
| Hester Biosciences Limited | 364.77 Million INR | -1478.556% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | -24.968% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 249.448% |
| Gufic Biosciences Limited | 2.89 Billion INR | -98.98% |
| Windlas Biotech Limited | 1.29 Billion INR | -343.309% |
| Procter & Gamble Health Limited | 2.78 Billion INR | -106.68% |
| Aarey Drugs & Pharmaceuticals Limited | 2.83 Million INR | -203307.062% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -20870.573% |
| Granules India Limited | 6.52 Billion INR | 11.797% |
| Aarti Drugs Limited | 7.14 Billion INR | 19.453% |
| Bal Pharma Limited | 214.56 Million INR | -2583.566% |
| Alkem Laboratories Limited | 19.46 Billion INR | 70.413% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 94.479% |
| Lincoln Pharmaceuticals Limited | 1.9 Billion INR | -202.052% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Bafna Pharmaceuticals Limited | 237.66 Million INR | -2322.821% |
| Biofil Chemicals and Pharmaceuticals Limited | 20.65 Million INR | -27776.162% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| Orchid Pharma Limited | 2.36 Billion INR | -143.876% |
| Medico Remedies Limited | 277.11 Million INR | -1977.851% |
| Ind-Swift Laboratories Limited | 2 Billion INR | -186.611% |
| Ipca Laboratories Limited | 29.59 Billion INR | 80.545% |
| Brooks Laboratories Limited | -72.25 Million INR | 8069.468% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -2210.161% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 77.272% |
| NATCO Pharma Limited | 25.96 Billion INR | 77.821% |
| Suven Life Sciences Limited | -1.22 Billion INR | 569.734% |
| Krebs Biochemicals & Industries Limited | - INR | -Infinity% |
| Strides Pharma Science Limited | 5.22 Billion INR | -10.186% |
| Indoco Remedies Limited | 1.52 Billion INR | -277.729% |
| Alpa Laboratories Limited | 61.51 Million INR | -9260.481% |
| Lasa Supergenerics Limited | -458 Million INR | 1357.213% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 239.928% |